ABT News
Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce Coronary Intravascular Lithotripsy System
Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce Coronary Intravascular Lithotripsy System Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational...
PR Newswire
Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce Coronary Intravascular Lithotripsy System
Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce Coronary Intravascular Lithotripsy System Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational...
PR Newswire
Abbott initiates pivotal trial for Cephea device, an innovative treatment for mitral heart valve disease
Abbott initiates pivotal trial for Cephea device, an innovative treatment for mitral heart valve disease Abbott initiates pivotal trial for Cephea device, an innovative treatment for mitral heart valve diseasePR NewswireABBOTT PARK, Ill., Oct. 29, 2026 CROWN-MV trial will evaluate the safety and...
PR Newswire
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
Based on the average brokerage recommendation (ABR), Abbott (ABT) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Zacks
Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now?
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Zacks
Abbott launches whole-genome sequencing Oncodetect molecular residual disease (MRD) test to detect traces of cancer during and after treatment
Abbott launches whole-genome sequencing Oncodetect molecular residual disease (MRD) test to detect traces of cancer during and after treatment Abbott launches whole-genome sequencing Oncodetect molecular residual disease (MRD) test to detect traces of cancer during and after treatmentPR...
PR Newswire
Abbott Laboratories vs. UnitedHealth: Does Health Innovation or Health Insurance Make for a Better Stock to Buy?
Key PointsAbbott Laboratories maintains a highly diversified healthcare business spanning medical technology, diagnostics, and nutrition...
Nasdaq News: Markets
Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect test in colorectal cancer
Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect test in colorectal cancer Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect test in...
PR Newswire
Abbott's Q3 Earnings Call Focuses on Nutrition Spin-Off and Outlook
Abbott plans to spin off its $8.5B Nutrition business by 2027 while cutting its 2026 sales growth outlook amid diabetes pricing and electrophysiology challenges.
Zacks
Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm
Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold Firm Nasdaq and Small Caps Lead Three Day Surge as Crude Slides and Blue Chips Hold FirmPR NewswireVANCOUVER, BC, Oct. 21, 2026 VANCOUVER, BC, Oct. 21, 2026 /PRNewswire/ -- Stock Preachers News Commentary - Three...
PR Newswire
Abbott Laboratories Q3 2026 Earnings Call Transcript
Abbott Laboratories (NYSE:ABT) reported third-quarter financial results on Wednesday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you by Benzingaread more...
Benzinga